Summary
Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated in a range of plant crops. Although the commercial exploitation is still pending, today various plant-based expression technologies have reached significant milestones through clinical testing in humans. Each of the protein manufacturing platforms in plants has specific benefits and drawbacks. We have engaged in comparing some of these production systems with respect to their performance: protein yield and quality. Using a specific tester protein (aprotinin), it was shown that functional aprotinin can be manufactured in plants in substantial amounts, as illustrated in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fischer, R., Stoger, E., Schillberg, S., Christou, P., and Twyman, R.M. (2004). Plantbased production of biopharmaceuticals. Curr. Opin. Plant Biol. 7, 152–158.
Kermode, A.R. (2006). Plants as factories for production of biopharmaceutical and bioindustrial proteins: lessons from cell biology. Can. J. Bot. 84, 679–694.
Stoger, E., Ma, J.K.-C, Fischer, R, and Christou, P. (2005). Sowing the seeds of success: pharmaceutical proteins. Curr. Opin. Biotechnol. 16, 167–173.
Hewlett, G. (1990). Apropos aprotinin: a review. Biotechnology 8, 565–568.
Apeler, H., Peters, J., Schröder, W., Schneider, K.-H., Lemm, G., Hinz, V., Rossouw, G.J., and Dembowsky, K. (2004). Expression, purification, biochemical and pharmacological characterization of a recombinant aprotinin variant. Arzneim.-Forsch./Drug Res. 54(8), 483–497.
Azzoni, A.R, Kusnadi, A.R., Miranda, E.A., and Nikolov, Z.L. (2002). Recombinant aprotinin produced in transgenic corn seed: extraction and purification studies. Biotechnol. Bioeng. 80(3), 268–276.
Svab, Z., and Maliga, P. (1993). High-frequency plastid transformation in tobacco by selection for a chimeric aadA gene. Proc. Natl. Acad. Sci. USA 90(3), 913–917.
Staub, J.M., Garcia, B., Graves, J., Hajdukiewicz, P.T., Hunter, P., Nehra, N., Paradkar, V., Schlittler, M., Carroll, J.A., Spatola, L., Ward, D., Ye, G., and Russel, DA. (2000). High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat. Biotechnol. 18(3), 333–338.
Rival, S., Wisniewski, J.-P., Langlais, A., Kaplan, H., Freyssinet, G., Vancanneyt, G., Vunsh, R., Perl, A., and Edelman, M. (2007). Spirodela (duckweed) as alternative production system for pharmaceuticals: a case study, aprotinin. Transgenic Res. 17(4), 503–513.
Zhong, G.-Y., Peterson, D., Delaney, D.E., Bailey, M., Witcher, D.R, Register, J.C., III, Bond, D., Li, C.-P., Marshall, L., Kulisek, E., Ritland, D., Meyer, T., Hood, E.E., and Howard, J.A. (1999). Commercial production of aprotinin in transgenic seeds. Mol. Breed. 5(4), 345–356.
Delaney, D., Jilka, J., Barker, D., Irwin, P., Poage, M., Woodard, S., Horn, M., Vinas, A., Beifuss, K., Barker, M., Wiggins, B., Drees, C, Harkey, R, Nikolov, Z., Hood, E., and Howard, J. (2002). Production of aprotinin in transgenic maize seeds for the pharmaceutical and cell culture markets. In: Vasil, I.K. (ed.) Plant biotechnology 2002 and beyond. Kluwer, Dordrecht, pp. 393–394.
Vojdani, F.S., Palmer, K.E., Garger, S.J., and Pogue, G.P. (2006). Plant produced recombinant aprotinin and aprotinin variants. Patent application US2006/0218667 A1.
Marillonnet, S., Thoeringer, C, Kandzia, R., Klimyuk, V., and Gleba, Y. (2005). Systemic Agrobacterium tumefaciensmediated transfection of viral replicons for efficient transient expression in plants. Nat. Biotechnol. 23(6), 718–723.
Giritch, A., Marillonnet, S., Engler, C, van Eldik, G., Botterman, J., Klimyuk, V., and Gleba, Y. (2006). Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc. Natl. Acad. Sci. USA 103(40), 14701–6.
Azzoni, A.R., Takahashi, K., Woodard, S.L., Miranda, E.A., and Nikolov, Z.L. (2005). Purification of recombinant aprotinin produced in trans genic corn seed: separation from CTI utilizing ion-exchange chromatography. Braz. J. Chem. Eng. 22 (3), 323–330.
Rivard, D., Anguenot, R., Brunelle, F., Quy Le, V., Vezina, L.-P., Trépanier, S., and Michaud, D. (2006). An in-built proteinase inhibitor system for the protection of recombinant proteins recovered from transgenic plants. Plant Biotechnol. 4, 359–368.
Kassel, B., and Laskowski, M. (1965). The basic trypsin inhibitor of bovine pancreas. V. The disulfide linkages. Biochem. Biophys. Res. Commun. 20, 463–468.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Vancanneyt, G., Dubald, M., Schröder, W., Peters, J., Botterman, J. (2009). A Case Study for Plant-Made Pharmaceuticals Comparing Different Plant Expression and Production Systems. In: Faye, L., Gomord, V. (eds) Recombinant Proteins From Plants. Methods in Molecular Biology™, vol 483. Humana Press. https://doi.org/10.1007/978-1-59745-407-0_12
Download citation
DOI: https://doi.org/10.1007/978-1-59745-407-0_12
Publisher Name: Humana Press
Print ISBN: 978-1-58829-978-9
Online ISBN: 978-1-59745-407-0
eBook Packages: Springer Protocols